Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
•
IPF
How do you counsel patients regarding prognosis following a diagnosis of IPF?
Related Questions
What is the duration of steroids that you prescribe for organizing pneumonia?
Do you administer immunosuppression to patients with idiopathic NSIP who have normal lung function and mild to moderate respiratory symptoms?
Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?
Do you monitor CBCs to assess for drug toxicity in patients on nintedanib?
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
What criteria do you use to decide when to perform a BAL in hypersensitivity pneumonitis?
Have you adopted the use of low dose morphine for treatment of cough in patients with IPF?
How do you approach a patient with sarcoidosis who cannot tolerate steroids and who is developing ILD?
Would you consider adding or switching to pirfenidone for a patient with progressing UIP (based on imaging and PFTs) who is currently on nintedanib?
